TM6SF2rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

(2015) Kuo-Chin Chang et al.   Clinical Gastroenterology and Hepatology

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

(2015) Marta Milano et al.   HEPATOLOGY

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

(2015) Paola Dongiovanni et al.   HEPATOLOGY

Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity

(2015) Silvia Sookoian et al.   HEPATOLOGY

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2

(2015) You Zhou et al.   JOURNAL OF HEPATOLOGY

TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism

(2015) Nicola Coppola et al.   LIVER INTERNATIONAL

Impact of common risk factors of fibrosis progression in chronic hepatitis C

(2014) S Rüeger et al.   GUT

Current and future HCV therapy: do we still need other anti-HCV drugs?

(2014) Salvatore Petta et al.   LIVER INTERNATIONAL

Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk

(2014) Oddgeir L Holmen et al.   NATURE GENETICS

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

(2014) Julia Kozlitina et al.   NATURE GENETICS

Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis

(2014) Masaya Sato et al.   PLoS One

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis

(2013) Mazen Noureddin et al.   HEPATOLOGY

Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C

(2012) Salvatore Petta et al.   Clinical Gastroenterology and Hepatology

The interaction of metabolic factors with HCV infection: Does it matter?

(2012) Elisabetta Bugianesi et al.   JOURNAL OF HEPATOLOGY

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

(2011) Eric Trépo et al.   HEPATOLOGY

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

(2011) Francesco Marabita et al.   HEPATOLOGY

Viral genotype-specific role of PNPLA3 , PPARG , MTTP, and IL28B in hepatitis C virus-associated steatosis

(2011) Tao Cai et al.   JOURNAL OF HEPATOLOGY

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1

(2010) Salvatore Petta et al.   HEPATOLOGY

Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

(2010) Luca Valenti et al.   HEPATOLOGY

Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial

(2009) James E. Everhart et al.   GASTROENTEROLOGY

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS